Cell Cure Neurosciences’ shareholders will receive an equity investment of $7.1M Read more…
BTIM’s Cell Cure Neurosciences and Hadasit Bio-Holdings have entered into an exclusive license option agreement with Teva Read more…
Founder and Director of Research, Henry McCusker enters his eighth (8) year at Scimitar Equity with past experience in sell-side analysis, buy-side management, corporate management and due diligence.
I started this blog to add commentary, update news flow and insightful opinions that are intelligent, fit to print and SEC compliant.